Notice · content is for research purposes. The peptides described are not approved for human consumption and do not constitute medical advice.
In my work specializing in molecular biochemistry and receptor pharmacology, I frequently examine the mechanisms through which short chains of amino acids interact with the central nervous system. Two of the most heavily researched molecules in this category are Selank and Semax. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences (RAS), these compounds have drawn the attention of neurobiologists worldwide. While they have a long history of clinical application in certain countries, in Western laboratories they remain the subjects of intensive in vitro and in vivo studies. This article explores the available scientific literature, mechanisms of action, and what modern cognitive models reveal about these peptides.
In biochemistry, short regulatory peptides act as signaling molecules that modulate various physiological processes.
Selank is a synthetic heptapeptide (composed of seven amino acids) that represents a modified analog of the naturally occurring peptide tuftsin. In the human body, tuftsin is primarily associated with the immune system and the stimulation of phagocytosis. Researchers have found that adding a specific peptide sequence (Pro-Gly-Pro) to its structure alters its pharmacokinetics, protects it from rapid enzymatic degradation, and directs its action toward the central nervous system.
Semax, on the other hand, is a synthetic heptapeptide based on a fragment of the adrenocorticotropic hormone (ACTH 4-10). ACTH is a key hormone in the hypothalamic-pituitary-adrenal axis, responsible for the body's response to stress. Similar to Selank, the structure of Semax is stabilized by adding a Pro-Gly-Pro sequence at the C-terminus. There are also modified versions such as NA-Semax (N-acetyl Semax), where acetylation at the N-terminus aims to further increase the molecule's stability during laboratory experiments by preventing exopeptidase activity.
Research on these molecules focuses on their role in neuromodulation, the expression of brain-derived neurotrophic factor (BDNF), and their impact on monoaminergic systems.
In animal models of stress and behavior, researchers observe that Selank interacts closely with the enkephalin system, which is involved in the regulation of nociception and emotional responses. A study published by Seredenin et al. shows that the administration of Selank in rats leads to the modulation of serotonin and dopamine metabolism in the cerebral cortex and hippocampus [1]. Other laboratory analyses demonstrate that the molecule can affect the GABAergic system, altering the affinity of GABA receptors for their endogenous ligands, which researchers correlate with the behavioral changes observed in animal models [2].
With Semax, scientists often focus on cognitive models and neuroprotection. In experiments using ischemic animal models (where blood flow to the brain is artificially restricted), researchers report that Semax stimulates the expression of BDNF and its TrkB receptors. According to published data from Dolotov et al., the peptide exhibits the ability to modulate inflammatory processes in brain tissue and support neuronal survival following induced oxidative stress [3]. Additional in vitro tests with cell cultures show that Semax influences the expression of genes related to the immune response and vascular function in the brain.
When examining the regulatory status of these molecules, it is critical to make a clear distinction between different jurisdictions and regulatory frameworks.
In the Russian Federation and some neighboring countries, Selank and Semax are officially registered and approved medicinal products. They were developed by the Institute of Molecular Genetics of the RAS and are manufactured for clinical use, prescribed for specific neurological indications, post-stroke recovery, or acute stress conditions.
In the European Union (including the EMA and the Bulgarian IAL), as well as in the United States (by the FDA), these compounds are NOT approved for human use. They are not registered as medicinal products or dietary supplements. In the Western world, they are exclusively classified as research-grade chemicals (research reagents). Their distribution in the EU and US is intended solely for laboratory preclinical studies, HPLC analyses, mass spectrometry, and experiments involving cell cultures or animal models.
Despite decades of research conducted primarily in Eastern Europe, significant gaps remain in the scientific understanding of these molecules on a global scale.
First, there is a lack of large-scale, multicenter, double-blind RCT (randomized controlled trials) in Western literature that meet modern standards for clinical evaluation of safety and efficacy across diverse populations. Second, the exact mechanism by which these peptides cross the blood-brain barrier under various administration methods (although believed to enter via the olfactory tract) continues to be a subject of debate in pharmacokinetic models. Third, the full gene expression profile induced by long-term cellular exposure to Selank or Semax requires further investigation using modern mass-spectrometry and transcriptomics to rule out potential off-target effects.
Q: What is the difference between Selank and Semax in laboratory models? A: Selank is based on the immunomodulatory peptide tuftsin and is primarily studied in animal models related to stress, behavioral responses, and GABA receptor modulation. Semax is an ACTH analog and is more frequently studied in the context of neuroprotection, ischemia, and cognitive function stimulation via BDNF elevation.
Q: Why do scientists study N-acetylated versions like Na-Semax? A: Acetylation of the N-terminus of the peptide chain is a chemical modification that scientists use to reduce the rapid degradation of the molecule by specific enzymes (exopeptidases). This increases the half-life of the peptide in in vivo models, allowing for prolonged observation of its effects.
Q: Are these peptides approved for clinical use in Europe? A: No. Neither Selank nor Semax is approved by the European Medicines Agency (EMA) or local EU regulatory bodies. They are strictly available as research substances for laboratory work.
[1] Seredenin, S. B., et al. (2008). "Effect of selank on the content of monoamines and their metabolites in the brain of rats." Bulletin of Experimental Biology and Medicine, 145(2), 221-224. [2] Kozlovskaya, M. M., et al. (2003). "Selank and its mechanisms of action in anxiety models." Neuroscience and Behavioral Physiology, 33(9), 853-857. [3] Dolotov, O. V., et al. (2006). "Semax, an analog of ACTH(4-10) with cognitive-enhancing effects, regulates BDNF expression." Brain Research, 1117(1), 54-60.
Research reagents for laboratory purposes. Not medicines; not approved for human use.
This article is entirely informative and educational in nature, based on a review of available scientific literature. The described molecules are research chemicals and are not intended for the diagnosis, prevention, or treatment of diseases. If you have health concerns, always consult a qualified medical professional.
No comments yet. Be the first.
Comments are reviewed before publishing.
